Skip to contents

Richard Steven Blumberg, MD
Senior Physician, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
75 Francis Street
Boston, MA 02115

Edit Profile

Research Narrative:

Dr. Richard S. Blumberg trained in internal medicine (The New York Hospital, 1982), infectious diseases (Massachusetts General Hospital, 1986) and gastroenterology & hepatology (Brigham & Women’s Hospital, 1989). He is currently Senior Physician in Medicine and Gastroenterology at Brigham and Women’s Hospital (BWH) where he leads the Division of Gastroenterology, Hepatology and Endoscopy, is Professor of Medicine at Harvard Medical School and co-Director of the Harvard Digestive Diseases Center. In addition, Dr. Blumberg serves on the Executive Advisory Committee of the Department of Medicine and is the incoming Chair of the Biomedical Research Institute at BWH. He has served as a member of the Immunology Sciences Study Section of NIAID, a member on the National Commission of Digestive Diseases of the NIDDK, scientific consultant to the Human Microbiome Project (NHGRI), a member of the Vaccine Branch External Advisory Board (NCI), Chair of the External Scientific Consultants for the Intestinal Stem Cell Consortium Initiative (NIDDK) and is currently on the Board of Scientific Councilors (NIAID). He served as the Chair of the National Scientific Advisory Committee of the Crohn’s & Colitis of America (2002-2005) and President of the Society for Mucosal Immunology (2007-2009). Dr. Blumberg is an elected member of the American Association of Clinical Investigation and the Association of American Physicians and the recipient of a MERIT Award from the NIH (2005), the William Beaumont Prize from the American Gastroenterological Association (2012) and the Distinguished Scientific Achievement Award from the Crohn’s and Colitis Foundation of America (2012). He is an NIH-funded investigator whose research program focuses on mucosal immunology and was Scientific Founder, Syntonix Pharmaceuticals (now Biogen-Hemophilia) that developed long-acting therapeutic agents successful in the treatment of chronic diseases such as hemophilia A and B.